US Authorities Approve Groundbreaking Sickle Cell Treatments, Including One That Uses CRISPR

December 9, 2023
IMG

The United States Food and Drug Administration (FDA) on Friday announced the approval of Casgevy, the first CRISPR gene-editing therapy for sickle cell disease, a debilitating genetic illness that affects over 100,000 Americans, the majority of whom are Black.

It is the first gene editing therapy ever to be used in humans, for sickle cell disease. The agency also approved a second treatment using conventional gene therapy for sickle cell that does not use gene editing.

Join our WhatsApp Channel

This development paves the way for thousands of patients in the United States to receive a treatment that has been described as a “functional cure” for eligible patients. The approval marks the first of two potential breakthroughs for the inherited blood disorder.

The gene editing treatment, called Exa-cel and using the brand name Casgevy, was jointly developed by Vertex Pharmaceuticals of Boston and CRISPR Therapeutics of Switzerland. It uses CRISPR, the Nobel Prize-winning gene editing tool, to snip patients’ DNA. For a small number of subjects in clinical trials, it corrected the effects of the mutation, which results in red blood cells that are shaped like sickles or crescents that become caught in blood vessels, blocking them.

The other approved therapy, called Lyfgenia and made by Bluebird Bio of Somerville, Mass., uses a common gene therapy method to add a good haemoglobin gene to patients’ DNA. Bluebird has 27 authorized centres and also plans to add more.

Both treatments work by genetically modifying a patient’s own stem cells. Until now, the only known cure for sickle cell disease was a bone marrow transplant from a donor, which carries the risk of rejection by the immune system, in addition to the difficult process of finding a matching donor.

Casgevy, which was approved for people ages 12 and older, removes the need for a donor. Using CRISPR, it edits the DNA found in a patient’s stem cells to remove the gene responsible for the devastating blood disorder caused by a single mutated gene.

“It’s a game-changer,” said Dr. Asmaa Ferdjallah, a pediatric hematologist and bone marrow transplant physician at the Mayo Clinic in Rochester, Minnesota.

“To really reimagine and re-discuss sickle cell disease as a curable disease and not as this painful and debilitating chronic disease is hope enough with this news.”

“This could be an equalizer for people with sickle cell because many patients cannot pursue career options” because of the illness.

“It’s something families have been aware of in the early research stage, and they’ve been very patiently waiting for years,” NBC News reports Ferdjallah as saying.

+ posts

Victor Ezeja

Victor Ezeja is a passionate journalist with seven years of experience writing on economy, politics and energy. He holds a Master's degree in Mass Communication.

Nze Duru Felicitates Akpabio @ 61
Previous Story

Nze Duru Felicitates Akpabio @ 61

IMG
Next Story

Tinubu’s Minister, Lalong Calls Himself ‘A Very Confused Man’

Latest from World News

Commonwealth Foreign Ministers Converge in New York for Key Meeting

The 25th Commonwealth Foreign Affairs Ministers Meeting (CFAMM) is set to take place on September 22, 2025, at the UN Headquarters in New York. The meeting, chaired by Rwanda’s Minister of Foreign Affairs and International Cooperation, Olivier J.P. Nduhungirehe, will bring together
Nze Duru Felicitates Akpabio @ 61
Previous Story

Nze Duru Felicitates Akpabio @ 61

IMG
Next Story

Tinubu’s Minister, Lalong Calls Himself ‘A Very Confused Man’

Don't Miss

Jensen Huang’s Nvidia Is Now A Trillion Dollar Company

In the bustling markets of Taipei, Taiwan, amidst the vibrant
Low Voters Turnout, As INEC Officials Wait In Bauchi

What You Should Know On Voting Procedures During Elections

Voting during an election is one of the most important